vs
Side-by-side financial comparison of American Express (AXP) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $18.9M, roughly 1.1× American Express). American Express runs the higher net margin — 15.7% vs -20.4%, a 36.1% gap on every dollar of revenue. On growth, American Express posted the faster year-over-year revenue change (11.4% vs 6.9%). Over the past eight quarters, Sight Sciences, Inc.'s revenue compounded faster (2.9% CAGR vs -95.6%).
American Express Company, together with its subsidiaries, provides charge and credit payment card products, and travel-related services worldwide. The company operates through three segments: Global Consumer Services Group, Global Commercial Services, and Global Merchant and Network Services. Its products and services include payment and financing products; network services; accounts payable expense management products and services; and travel and lifestyle services. The company's products an...
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
AXP vs SGHT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.9M | $20.4M |
| Net Profit | $3.0M | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | — | -18.0% |
| Net Margin | 15.7% | -20.4% |
| Revenue YoY | 11.4% | 6.9% |
| Net Profit YoY | 15.0% | 64.9% |
| EPS (diluted) | — | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $18.9M | — | ||
| Q4 25 | $10.9B | $20.4M | ||
| Q3 25 | $10.4B | $19.9M | ||
| Q2 25 | $10.3B | $19.6M | ||
| Q1 25 | $9.6B | $17.5M | ||
| Q4 24 | $10.0B | $19.1M | ||
| Q3 24 | $9.7B | $20.2M | ||
| Q2 24 | $9.8B | $21.4M |
| Q1 26 | $3.0M | — | ||
| Q4 25 | $2.5B | $-4.2M | ||
| Q3 25 | $2.9B | $-8.2M | ||
| Q2 25 | $2.9B | $-11.9M | ||
| Q1 25 | $2.6B | $-14.2M | ||
| Q4 24 | $2.2B | $-11.8M | ||
| Q3 24 | $2.5B | $-11.1M | ||
| Q2 24 | $3.0B | $-12.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% |
| Q1 26 | — | — | ||
| Q4 25 | 28.2% | -18.0% | ||
| Q3 25 | 36.7% | -39.7% | ||
| Q2 25 | 34.4% | -59.6% | ||
| Q1 25 | 34.6% | -79.2% | ||
| Q4 24 | 27.7% | -62.5% | ||
| Q3 24 | 33.0% | -55.7% | ||
| Q2 24 | 38.6% | -59.2% |
| Q1 26 | 15.7% | — | ||
| Q4 25 | 22.5% | -20.4% | ||
| Q3 25 | 27.9% | -41.0% | ||
| Q2 25 | 28.0% | -61.0% | ||
| Q1 25 | 26.8% | -80.8% | ||
| Q4 24 | 21.8% | -62.1% | ||
| Q3 24 | 25.8% | -54.9% | ||
| Q2 24 | 30.7% | -57.7% |
| Q1 26 | — | — | ||
| Q4 25 | $3.52 | $-0.07 | ||
| Q3 25 | $4.14 | $-0.16 | ||
| Q2 25 | $4.08 | $-0.23 | ||
| Q1 25 | $3.64 | $-0.28 | ||
| Q4 24 | $3.04 | $-0.23 | ||
| Q3 24 | $3.49 | $-0.22 | ||
| Q2 24 | $4.15 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $92.0M |
| Total DebtLower is stronger | $60.4M | $42.4M |
| Stockholders' EquityBook value | $34.0M | $63.9M |
| Total Assets | $308.9M | $115.3M |
| Debt / EquityLower = less leverage | 1.78× | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $742.0M | $92.0M | ||
| Q3 25 | $1.3B | $92.4M | ||
| Q2 25 | $197.0M | $101.5M | ||
| Q1 25 | $261.0M | $108.8M | ||
| Q4 24 | $221.0M | $120.4M | ||
| Q3 24 | $120.0M | $118.6M | ||
| Q2 24 | $188.0M | $118.2M |
| Q1 26 | $60.4M | — | ||
| Q4 25 | $56.4B | $42.4M | ||
| Q3 25 | $57.8B | $42.4M | ||
| Q2 25 | $58.2B | $42.4M | ||
| Q1 25 | $51.2B | $42.4M | ||
| Q4 24 | $49.7B | $40.0M | ||
| Q3 24 | $53.5B | $37.1M | ||
| Q2 24 | $51.5B | $35.0M |
| Q1 26 | $34.0M | — | ||
| Q4 25 | $33.5B | $63.9M | ||
| Q3 25 | $32.4B | $64.3M | ||
| Q2 25 | $32.3B | $70.0M | ||
| Q1 25 | $31.2B | $77.6M | ||
| Q4 24 | $30.3B | $87.5M | ||
| Q3 24 | $29.7B | $95.0M | ||
| Q2 24 | $29.5B | $101.6M |
| Q1 26 | $308.9M | — | ||
| Q4 25 | $300.1B | $115.3M | ||
| Q3 25 | $297.6B | $116.3M | ||
| Q2 25 | $295.6B | $122.0M | ||
| Q1 25 | $282.2B | $129.7M | ||
| Q4 24 | $271.5B | $142.8M | ||
| Q3 24 | $271.0B | $143.6M | ||
| Q2 24 | $272.2B | $149.7M |
| Q1 26 | 1.78× | — | ||
| Q4 25 | 1.68× | 0.66× | ||
| Q3 25 | 1.78× | 0.66× | ||
| Q2 25 | 1.80× | 0.61× | ||
| Q1 25 | 1.64× | 0.55× | ||
| Q4 24 | 1.64× | 0.46× | ||
| Q3 24 | 1.80× | 0.39× | ||
| Q2 24 | 1.74× | 0.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-1.8M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -9.7% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | $-1.8M | ||
| Q3 25 | $6.2B | $-8.7M | ||
| Q2 25 | $4.4B | $-7.5M | ||
| Q1 25 | $4.8B | $-11.6M | ||
| Q4 24 | $5.8B | $-3.5M | ||
| Q3 24 | $-1.8B | $362.0K | ||
| Q2 24 | $4.5B | $-9.5M |
| Q1 26 | — | — | ||
| Q4 25 | $2.3B | $-2.0M | ||
| Q3 25 | $5.6B | $-8.9M | ||
| Q2 25 | $3.7B | $-7.8M | ||
| Q1 25 | $4.3B | — | ||
| Q4 24 | $5.3B | $-3.6M | ||
| Q3 24 | $-2.3B | $311.0K | ||
| Q2 24 | $4.0B | $-9.5M |
| Q1 26 | — | — | ||
| Q4 25 | 21.4% | -9.7% | ||
| Q3 25 | 53.6% | -44.7% | ||
| Q2 25 | 36.3% | -39.6% | ||
| Q1 25 | 45.0% | — | ||
| Q4 24 | 53.1% | -18.9% | ||
| Q3 24 | -23.3% | 1.5% | ||
| Q2 24 | 40.4% | -44.7% |
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 0.8% | ||
| Q3 25 | 6.3% | 0.9% | ||
| Q2 25 | 6.0% | 1.1% | ||
| Q1 25 | 4.5% | 0.0% | ||
| Q4 24 | 5.0% | 0.7% | ||
| Q3 24 | 4.7% | 0.3% | ||
| Q2 24 | 5.8% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | 1.25× | — | ||
| Q3 25 | 2.15× | — | ||
| Q2 25 | 1.51× | — | ||
| Q1 25 | 1.84× | — | ||
| Q4 24 | 2.66× | — | ||
| Q3 24 | -0.72× | — | ||
| Q2 24 | 1.50× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXP
| Discount revenue | $9.5M | 50% |
| Other | $8.9M | 47% |
| Deposits with banks and other | $512.0K | 3% |
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
